Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lacosamide IV vs Oral in Healthy Chinese Males
NCT03204474Phase 1Completed
- Sponsor
- UCB
- Start
- Jun 2017
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lacosamide in epilepsy (2 arms), sponsored by UCB. Primary endpoints: Maximum plasma concentration at 72 hours, Area under the plasma concentration-time curve from time zero to last quantifiable concentration at 72 hours and 1 more. Started Jun 2017; status: completed.
02
Drugs
lacosamide
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03204474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204474.